Bunge CapEx decreased by 37.5% to $336.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.4%, from $310.00M to $336.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 44.2% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $99.75M | $99.75M | $99.75M | $138.75M | $138.75M | $138.75M | $138.75M | $173.00M | $368.00M | $264.00M | $317.00M | $236.00M | $297.00M | $354.00M | $489.00M | $310.00M | $406.00M | $469.00M | $538.00M | $336.00M |
| QoQ Change | — | +0.0% | +0.0% | +39.1% | +0.0% | +0.0% | +0.0% | +24.7% | +112.7% | -28.3% | +20.1% | -25.6% | +25.8% | +19.2% | +38.1% | -36.6% | +31.0% | +15.5% | +14.7% | -37.5% |
| YoY Change | — | — | — | — | +39.1% | +39.1% | +39.1% | +24.7% | +165.2% | +90.3% | +128.5% | +36.4% | -19.3% | +34.1% | +54.3% | +31.4% | +36.7% | +32.5% | +10.0% | +8.4% |